In Conversation With Novo Nordisk CMO: The Ongoing Fight Against Diabetes
Executive Summary
Stephen Gough has kept his connections with Oxford University and will see collaborations between the two expand next month with the opening of the Novo Nordisk Research Centre Oxford. The executive spoke to Scrip.
You may also be interested in...
Novo Nordisk Plans Value-based Contracts For GLP-1 Agonist Ozempic
Company aims to shift gradually away from once-daily GLP-1 Victoza (liraglutide) toward once-weekly Ozempic (semaglutide).
Novo Nordisk CSO Thomsen Assesses The Competition In Diabetes
The world of diabetes will increasingly be dominated by Novo Nordisk and Eli Lilly, the Danish group's chief science officer tells Scrip.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.